Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study

Autor: Alroughani, Raed, Al-Hashel, Jasem, Ahmed, Samar Farouk
Zdroj: In Clinical Neurology and Neurosurgery May 2024 240
Databáze: ScienceDirect
Externí odkaz: